glp-1 drug novo nordisk promotes new receptor agonist to fight diabetes, obesity < Pharma < Article GLP-1 Drugs Are Coming, and

Food and Drug Administration (FDA) approved the GLP-1 agonist Wegovy to treat MASH, a type of liver disease

Forty-four percent of firms with 1,000 to 4,999 workers, and 59% of firms with 5,000 or more workers, say that the use of these medications for weight loss was higher than expected

18.3 2 pmol/mg protein

& Nauck, M

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation

Novo Nordisk reported the results from the STEP 1 extension trial on the impact of treatment withdrawal, which found that one year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss